vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Tronox Holdings plc (TROX). Click either name above to swap in a different company.

Tronox Holdings plc is the larger business by last-quarter revenue ($760.0M vs $749.2M, roughly 1.0× CLOVER HEALTH INVESTMENTS, CORP.). On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (62.0% vs 4.1%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (45.0% CAGR vs -3.7%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Tronox Limited is an American worldwide chemical company involved in the titanium products industry with approximately 6,500 employees. Following its acquisition of the mineral sands business formerly belonging to South Africa's Exxaro Resources, Tronox is the largest fully integrated seller and marketer of titanium dioxide (TiO2) pigment, which provides brightness to applications such as coatings, plastics and paper. Tronox mines titanium-bearing mineral sands and operates upgrading faciliti...

CLOV vs TROX — Head-to-Head

Bigger by revenue
TROX
TROX
1.0× larger
TROX
$760.0M
$749.2M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+57.9% gap
CLOV
62.0%
4.1%
TROX
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
45.0%
-3.7%
TROX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CLOV
CLOV
TROX
TROX
Revenue
$749.2M
$760.0M
Net Profit
$27.3M
Gross Margin
0.0%
Operating Margin
3.6%
Net Margin
3.6%
Revenue YoY
62.0%
4.1%
Net Profit YoY
EPS (diluted)
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
TROX
TROX
Q1 26
$749.2M
$760.0M
Q4 25
$487.7M
$730.0M
Q3 25
$496.6M
$699.0M
Q2 25
$477.6M
$731.0M
Q1 25
$462.3M
$738.0M
Q4 24
$337.0M
$676.0M
Q3 24
$331.0M
$804.0M
Q2 24
$356.3M
$820.0M
Net Profit
CLOV
CLOV
TROX
TROX
Q1 26
$27.3M
Q4 25
$-49.3M
$-176.0M
Q3 25
$-24.4M
$-99.0M
Q2 25
$-10.6M
$-84.0M
Q1 25
$-1.3M
$-111.0M
Q4 24
$-22.1M
$-30.0M
Q3 24
$-9.2M
$-25.0M
Q2 24
$7.4M
$16.0M
Gross Margin
CLOV
CLOV
TROX
TROX
Q1 26
0.0%
Q4 25
5.3%
Q3 25
7.4%
Q2 25
10.8%
Q1 25
13.4%
Q4 24
17.3%
Q3 24
24.5%
15.9%
Q2 24
30.3%
18.3%
Operating Margin
CLOV
CLOV
TROX
TROX
Q1 26
3.6%
Q4 25
-10.1%
-15.6%
Q3 25
-4.9%
-6.2%
Q2 25
-2.2%
-4.8%
Q1 25
-0.3%
-8.3%
Q4 24
-6.4%
7.1%
Q3 24
-2.7%
6.7%
Q2 24
2.0%
9.3%
Net Margin
CLOV
CLOV
TROX
TROX
Q1 26
3.6%
Q4 25
-10.1%
-24.1%
Q3 25
-4.9%
-14.2%
Q2 25
-2.2%
-11.5%
Q1 25
-0.3%
-15.0%
Q4 24
-6.6%
-4.4%
Q3 24
-2.8%
-3.1%
Q2 24
2.1%
2.0%
EPS (diluted)
CLOV
CLOV
TROX
TROX
Q1 26
$0.05
Q4 25
$-1.11
Q3 25
$-0.63
Q2 25
$-0.53
Q1 25
$-0.70
Q4 24
$-0.19
Q3 24
$-0.16
Q2 24
$0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
TROX
TROX
Cash + ST InvestmentsLiquidity on hand
$177.6M
$126
Total DebtLower is stronger
$133
Stockholders' EquityBook value
$339.4M
$1.3K
Total Assets
$697.7M
$6.1K
Debt / EquityLower = less leverage
0.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
TROX
TROX
Q1 26
$177.6M
$126
Q4 25
$78.3M
$199.0M
Q3 25
$185.0M
Q2 25
$132.0M
Q1 25
$138.0M
Q4 24
$194.5M
$151.0M
Q3 24
$288.0M
$167.0M
Q2 24
$254.8M
$201.0M
Total Debt
CLOV
CLOV
TROX
TROX
Q1 26
$133
Q4 25
$3.1B
Q3 25
$3.1B
Q2 25
$2.7B
Q1 25
$2.8B
Q4 24
$2.8B
Q3 24
$2.8B
Q2 24
$2.8B
Stockholders' Equity
CLOV
CLOV
TROX
TROX
Q1 26
$339.4M
$1.3K
Q4 25
$308.7M
$1.4B
Q3 25
$340.9M
$1.6B
Q2 25
$344.2M
$1.6B
Q1 25
$336.1M
$1.7B
Q4 24
$341.1M
$1.8B
Q3 24
$342.2M
$1.9B
Q2 24
$324.9M
$1.9B
Total Assets
CLOV
CLOV
TROX
TROX
Q1 26
$697.7M
$6.1K
Q4 25
$541.0M
$6.2B
Q3 25
$559.7M
$6.3B
Q2 25
$575.0M
$6.2B
Q1 25
$583.7M
$6.1B
Q4 24
$580.7M
$6.0B
Q3 24
$653.0M
$6.2B
Q2 24
$674.2M
$6.1B
Debt / Equity
CLOV
CLOV
TROX
TROX
Q1 26
0.10×
Q4 25
2.21×
Q3 25
2.01×
Q2 25
1.67×
Q1 25
1.64×
Q4 24
1.57×
Q3 24
1.45×
Q2 24
1.47×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
TROX
TROX
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$53.0M
FCF MarginFCF / Revenue
7.0%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-86.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
TROX
TROX
Q1 26
Q4 25
$-66.9M
$121.0M
Q3 25
$12.1M
$-57.0M
Q2 25
$5.4M
$28.0M
Q1 25
$-16.3M
$-32.0M
Q4 24
$34.8M
$82.0M
Q3 24
$50.0M
$87.0M
Q2 24
$44.8M
$160.0M
Free Cash Flow
CLOV
CLOV
TROX
TROX
Q1 26
$53.0M
Q4 25
$-69.0M
$53.0M
Q3 25
$11.4M
$-137.0M
Q2 25
$4.8M
$-55.0M
Q1 25
$-16.5M
$-142.0M
Q4 24
$33.3M
$-35.0M
Q3 24
$49.6M
$-14.0M
Q2 24
$44.4M
$84.0M
FCF Margin
CLOV
CLOV
TROX
TROX
Q1 26
7.0%
Q4 25
-14.1%
7.3%
Q3 25
2.3%
-19.6%
Q2 25
1.0%
-7.5%
Q1 25
-3.6%
-19.2%
Q4 24
9.9%
-5.2%
Q3 24
15.0%
-1.7%
Q2 24
12.5%
10.2%
Capex Intensity
CLOV
CLOV
TROX
TROX
Q1 26
0.0%
Q4 25
0.4%
9.3%
Q3 25
0.1%
11.4%
Q2 25
0.1%
11.4%
Q1 25
0.0%
14.9%
Q4 24
0.5%
17.3%
Q3 24
0.1%
12.6%
Q2 24
0.1%
9.3%
Cash Conversion
CLOV
CLOV
TROX
TROX
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
6.04×
10.00×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons